Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Allergan/Medytox

Drug Profile

Botulinum toxin A - Allergan/Medytox

Alternative Names: Botulift; Cunox; Innotox; KbtxA; Liquid-type botulinum toxin type A - Allergan; Meditoxin; MT 10107; MT 10109; MT10109L; Neuronox; NivobotulinumtoxinA; Siax

Latest Information Update: 15 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medy-Tox
  • Developer Allergan; Medytox
  • Class Analgesics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase III Facial wrinkles; Hyperhidrosis; Torticollis
  • Phase II Hypertrophy
  • Phase I Overactive bladder

Most Recent Events

  • 10 Jan 2019 Allergan plans a phase III trial for Glabellar lines in the US (Injection) (NCT03795922)
  • 02 Jan 2019 Allergan plans a Phase III trial for Facial wrinkles in USA (NCT03785145)
  • 12 Dec 2018 Phase-III clinical trials in Glabellar lines in Russia (Injection) (NCT03837561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top